講師
Date:26 July (Wednesday)
Time:12:20 – 13:50 (GMT+8)
Vice President International Medical Affairs
AstraZeneca
Pei-Chieh currently leads more than 80 countries in Asia, Middle East & Africa and Latin America, as well as, Australia and Russia in Medical Affairs. In previous roles within the company, she has been the Medical Director for Taiwan and Asia Area covering the entire range of diseases and molecules from the company, as well as, having leading the Oncology team in International. Current focus on innovation and partnership within AstraZeneca’s International Medical team, most recently exemplified by the SLUSH partnership, has made leveraging advanced technology and synergistic external partnership as one of the main approaches in how AstraZeneca approaches clinical obstacles to best patient care.
Pei-Chieh has more than 10 years of solid experience in medical affairs prior to AstraZeneca through her roles in Roche, Pfizer and Novartis both in regional and local offices, covering disease areas such as infectious diseases, cardiovascular diseases, immunology, as well as, oncology. Pei-Chieh obtained her undergraduate and graduate degree both in California in the United States. She is educated as a clinical pharmacist with a Pharm.D. degree from the University of California, San Francisco (UCSF).
AstraZeneca is a global, science-led, patient-focused pharmaceutical company. Inspired by our purpose and values, we believe in transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. In a world where healthcare and the ecosystem is constantly changing, we believe working closely with partners inside and outside our industry, co-creating innovative solutions that address patients’ needs is central to create significant impact in patient lives. To create the best possible futures, we must work together. A.Catalyst Network addresses this through a dynamic global network of 20+ AstraZeneca health innovation hubs that brings digital, R&D and commercial together to create a home for patient-enabled innovation.